CA3095709A1 - Novel combinations of a tubulin polymerization inhibitor and a poly (adp-ribose) polymerase (parp) inhibitor for use in the treatment of cancer - Google Patents

Novel combinations of a tubulin polymerization inhibitor and a poly (adp-ribose) polymerase (parp) inhibitor for use in the treatment of cancer Download PDF

Info

Publication number
CA3095709A1
CA3095709A1 CA3095709A CA3095709A CA3095709A1 CA 3095709 A1 CA3095709 A1 CA 3095709A1 CA 3095709 A CA3095709 A CA 3095709A CA 3095709 A CA3095709 A CA 3095709A CA 3095709 A1 CA3095709 A1 CA 3095709A1
Authority
CA
Canada
Prior art keywords
cancer
indo1
combination
inhibitor
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3095709A
Other languages
English (en)
French (fr)
Inventor
Marita Hogberg
Stefan Rehnmark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NOVIGA RESEARCH AB
Original Assignee
NOVIGA RESEARCH AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NOVIGA RESEARCH AB filed Critical NOVIGA RESEARCH AB
Publication of CA3095709A1 publication Critical patent/CA3095709A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3095709A 2018-04-05 2019-04-04 Novel combinations of a tubulin polymerization inhibitor and a poly (adp-ribose) polymerase (parp) inhibitor for use in the treatment of cancer Pending CA3095709A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1850380 2018-04-05
SE1850380-5 2018-04-05
PCT/SE2019/050312 WO2019194738A1 (en) 2018-04-05 2019-04-04 Novel combinations of a tubulin polymerization inhibitor and a poly (adp-ribose) polymerase (parp) inhibitor for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
CA3095709A1 true CA3095709A1 (en) 2019-10-10

Family

ID=68101552

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3095709A Pending CA3095709A1 (en) 2018-04-05 2019-04-04 Novel combinations of a tubulin polymerization inhibitor and a poly (adp-ribose) polymerase (parp) inhibitor for use in the treatment of cancer

Country Status (6)

Country Link
US (1) US11590130B2 (enExample)
EP (1) EP3773592B1 (enExample)
JP (1) JP7372253B2 (enExample)
CN (1) CN111936143A (enExample)
CA (1) CA3095709A1 (enExample)
WO (1) WO2019194738A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016229294B2 (en) 2015-03-06 2021-11-04 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a RAS mutation
KR20180105685A (ko) 2016-02-08 2018-09-28 비욘드스프링 파마수티컬스, 인코포레이티드. 투카레솔 또는 이의 유사체를 함유하는 조성물
JP7025416B2 (ja) 2016-06-06 2022-02-24 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 好中球減少症を低減させるための組成物および方法
WO2018129381A1 (en) 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
BR112019015974A2 (pt) 2017-02-01 2020-03-31 Beyondspring Pharmaceuticals, Inc. Método para reduzir neutropenia
JP2023524530A (ja) * 2020-05-04 2023-06-12 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 免疫原性が低い癌の癌細胞死滅を増強するための３剤併用療法
CA3215047A1 (en) 2021-04-09 2022-10-13 Lan Huang Therapeutic compositions and methods for treating tumors
CN121127241A (zh) * 2023-03-10 2025-12-12 万春药业公司 肿瘤联合治疗及使用方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1976515A2 (en) 2006-01-17 2008-10-08 Abbott Laboratories Combination therapy with parp inhibitors
US20100249112A1 (en) 2007-05-25 2010-09-30 Astrazeneca R&D Combination of chk and parp inhibitors for the treatment of cancers
EP2217244A4 (en) 2007-11-12 2011-08-31 Bipar Sciences Inc TREATMENT OF NUTRITIONAL CANCER AND EGG CANCER WITH A PARP INHIBITOR ALONE OR IN COMBINATION WITH ANTITUMOROUS MEDICINES
RU2010128107A (ru) 2007-12-07 2012-01-20 Байпар Сайенсиз, Инк. (Us) Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp
CN101981013B (zh) 2008-03-27 2013-05-29 詹森药业有限公司 作为parp和微管蛋白聚合抑制剂的四氢菲啶酮和四氢环戊二烯并喹啉酮
ES2367760T3 (es) 2008-03-27 2011-11-08 Janssen Pharmaceutica, N.V. Derivados de quinazolinona como inhibidores de la polimerización de la tubulina.
CN102307475A (zh) 2009-02-04 2012-01-04 彼帕科学公司 用与生长因子抑制剂组合的parp抑制剂治疗肺癌
EP2459561A1 (en) 2009-07-30 2012-06-06 Takeda Pharmaceutical Company Limited Poly (adp-ribose) polymerase (parp) inhibitors
EP2576514A1 (en) * 2010-06-04 2013-04-10 Exonhit Sa Substituted isoquinolines and their use as tubulin polymerization inhibitors
DK2688883T3 (en) 2011-03-24 2016-09-05 Noviga Res Ab pyrimidine
TWI577693B (zh) 2011-05-31 2017-04-11 江蘇康緣藥業股份有限公司 聚（ａｄｐ-核糖）聚合酶之三環抑制劑
US9132120B1 (en) 2012-04-02 2015-09-15 Stc.Unm Targeting abnormal DNA repair in therapy-resistant breast and pancreatic cancers
JP6615746B2 (ja) 2013-04-09 2019-12-04 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 腫瘍選択的併用療法
US10195175B2 (en) * 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
WO2017013593A1 (en) 2015-07-22 2017-01-26 Lupin Limited Isoquinolinone derivatives as parp inhibitors
EP3380454A4 (en) 2015-11-20 2019-04-03 Lee, Hoyun CHINOLINE-CHALCON COMPOUNDS AND USES THEREOF
WO2017223516A1 (en) 2016-06-24 2017-12-28 The Regents Of The University Of California Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer

Also Published As

Publication number Publication date
CN111936143A (zh) 2020-11-13
US20210052583A1 (en) 2021-02-25
EP3773592A4 (en) 2022-02-23
JP7372253B2 (ja) 2023-10-31
WO2019194738A1 (en) 2019-10-10
EP3773592A1 (en) 2021-02-17
JP2021519262A (ja) 2021-08-10
EP3773592B1 (en) 2025-09-10
US11590130B2 (en) 2023-02-28

Similar Documents

Publication Publication Date Title
US11590130B2 (en) Combinations of a tubulin polymerization inhibitor and a poly (ADP-ribose) polymerase (PARP) inhibitor for use in the treatment of cancer
Neckers et al. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics–an update
JP6783224B2 (ja) 肺の非小細胞癌腫及び卵巣癌を処置するためのジアンヒドロガラクチトール及びその類縁体又は誘導体の使用
TWI762784B (zh) Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途
CN110730663B (zh) 阿帕替尼和c-Met抑制剂联合在制备治疗肿瘤的药物中的用途
CN107530336B (zh) 组合使用mdm2抑制剂和btk抑制剂的治疗方法
JP2008514726A (ja) ヘッジホッグ阻害剤、放射線及び化学療法薬の併用療法
CN101332301A (zh) 一种抗肿瘤组合物及其应用
CN106132412A (zh) 治疗癌症的新方法
US12162898B2 (en) Injectable gold-based pharmaceutical composition
JP7636322B2 (ja) 癌を処置するためのマドラシン誘導体化合物、組成物およびこれらの使用
US20250248993A1 (en) Camptothecin derivatives that bind to ddx5 protein and prodrugs thereof
Abe et al. 356 characterization of TAS-117, a novel, highly potent and selective inhibitor of AKT
Sivák Overcoming cancer resistance to chemotherapy through HPMA copolymer conjugates
Coyne et al. Role of HSP90 Inhibitors in the Treatment
Neuwelt et al. Silmitasertib. Casein kinase 2 (CK2) inhibitor, Treatment of solid and hematologic malignancies
Chen et al. The induction of orphan nuclear receptor Nur77 expression by n-butylenephthalide aspharmaceuticals on hepatocellular carcinoma (HCC) cells therapy
Bai et al. Design characterization and in vitro applications of novel chemotactic peptide-based drug delivery systems against cancer
Sandhu et al. 352 Final Results of the First in Man Trial of MK4827, a Poly (ADP-ribose) Polymerase (PARP) Inhibitor with Antitumor Activity in BRCA Carriers and Sporadic Cancer Patients
JP2014091711A (ja) Ｈｓｐ９０阻害剤と抗腫瘍性白金錯体との組み合わせ
KR20210087972A (ko) 암 치료를 위한 암 치료제와 병용된 IRE1α 억제제
Cole Alectinib Hydrochloride
JP2014034533A (ja) Ｈｓｐ９０阻害剤とｅｇｆｒチロシンキナーゼ阻害剤の組み合わせ

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240318

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250324

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250324

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250324

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250416

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250818